MultivisionDx has built a computer-vision platform that analyses multiplexed tumour biopsy images to map protein expression, cellular morphology, spatial arrangements and micro-environment composition, generating unique "cancer fingerprints" for each patient. These fingerprints have been validated in a cohort of 650 patients and published in Cell, showing more accurate prediction of treatment response than current clinical criteria. Spun out of the University of Helsinki in April 2025, the company is led by CEO Michael Wittinger and CSO Karolina Punovuori alongside three other co-founders. The team previously secured a €680k Business Finland grant in 2022 to begin commercialising the technology. With its newly raised capital, MultivisionDx plans to develop diagnostic tests, complete clinical validation studies and form partnerships with international hospitals and research groups. Over the next 18 months the founders aim to advance spatial biology from research settings into routine diagnostics, enabling clinicians to tailor cancer therapies more precisely.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2025